EDX Medical Group PLC Commercial Director appointment

TIDMEDX

EDX Medical Group PLC

12 July 2023

EDX Medical Group plc announces Erik Jensen as

Commercial Director, UK & Northern Europe

EDX Medical Group Plc -- EDX

12 July 2023

EDX Medical Group PLC ("EDX Medical" or the "Company"), which develops innovative digital diagnostic products and services enabling cost effective and timely delivery of personalised treatment for cancer, heart disease, neurology and infectious diseases, today announces that Erik Jensen will be joining the international senior management team of the company as Commercial Director, UK & Northern Europe. Erik will be based in the markets supported by colleagues at the Company's Head Office in Cambridge, UK.

Erik holds an MSc. in Economics & Business Administration from Copenhagen Business School, Denmark, and has completed additional commercial training whilst employed by Becton Dickinson and Abbott laboratories. He is fluent in several European languages and has previously held sales and business development roles based in Denmark, Norway and Sweden. In recent years he was Managing Director of RefLab, an in vitro diagnostics company specialised in allergy and auto-immune disease testing and pre-clinical contract research based in Denmark and managed the 'drugs of abuse' testing service for Abbott Laboratories in the Nordic region.

Commenting on his appointment Erik said: "I'm exceptionally excited at the opportunity to bring the pipeline of innovative EDX Medical products and services to clients in the UK and Nordic region, supporting our clients with the tools to obtain key patient data, enabling them to pioneer the adoption of personalised medicine for their patients."

Dr Mike Hudson, Chief Executive of EDX Medical Group PLC, added: "It gives me great pleasure to welcome Erik to EDX and particularly to be able to work with him to establish commercial operations in the UK and his home territory in the Nordic region. He's an excellent ambassador for the company and we are confident that he will quickly establish himself as a well-respected partner for our growing network of clients and partners. He will lead the launch of laboratory tests for drug safety, cancer diagnosis and treatment optimisation as well as a new range of Point of Care tests for the UK pharmacy sector."

Contacts:

 
 EDX Medical PLC 
 Dr Mike Hudson (Chief Executive Officer)    +44 (0)7812 345 301 
                                              mike@edxmedical.co.uk 
 
 Oberon Capital 
 Nick Lovering (Corporate Adviser) 
  Adam Pollock (Corporate Broking) 
  Mike Seabrook (Corporate Broking)          +44 (0)20 3179 5300 
 
 Media House International 
 Ramsay Smith (Executive Director)           +44 (0)7788 414856 
                                              ramsay@mediahouse.co.uk 
  Gary McQueen (Associate Director)           + 44 (0)7834 694609 
                                              gary@mediahouse.co.uk

Notes for Editors:

About EDX Medical Group

www.edxmedical.co.uk

EDX Medical Group PLC develops innovative digital diagnostic products and services, enabling cost effective and timely delivery of personalised treatment for cancer, heart disease, neurology and infectious diseases. The company is listed on the Access Segment of the AQSE Growth Market (TIDM: EDX).

EDX Medical was founded by Professor Sir Christopher Evans, OBE, a medical and life sciences entrepreneur with more than 30 years of experience, together with CEO, Dr Mike Hudson.

By translating clinical insights into pragmatic solutions combining advanced biological and digital technologies, EDX Medical seeks to cost-effectively improve the detection and characterisation of disease in order to personalise treatment in a timely fashion. Early disease detection and biologically-based personal treatment optimisation is considered to be the most impactful way of reducing deaths and lowering the cost of healthcare globally.

EDX Medical operates a molecular biology and diagnostics laboratory in Cambridge, UK, and the 100%-owned subsidiary "Torax Biosciences Ltd" ( www.toraxbiosciences.co.uk ) with a satellite operation in Ireland. EDX Medical provides testing and genomic sequencing services, undertakes quality assurance, conducts research & development (R&D) and has established expertise in the design, development, validation and sourcing of diagnostic testing solutions to ISO 13485. Key laboratory tests performed by the Company have been accredited to ISO 15189 by the United Kingdom Accreditation Service (UKAS).

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRAGPURPMUPWGAG

(END) Dow Jones Newswires

July 12, 2023 02:00 ET (06:00 GMT)

EDX Medical (AQSE:EDX)
過去株価チャート
から 4 2024 まで 5 2024